接受肿瘤坏死因子抑制剂治疗的轴性脊柱关节炎患者中患者报告结局指标的性别差异及其与临床因素的关联
研究纳入15个EuroSpA注册中心开始首次TNFi治疗的axSpA患者,分析BASDAI和BASFI的性别差异。女性评分始终更差,BASDAI性别差异从基线4.3单位增至6个月8.0单位,BASFI从2.2增至4.6。基线特征不能完全解释这些差异。
要点
- 女性axSpA患者首次TNFi治疗后BASDAI和BASFI评分始终差于男性。
- BASDAI性别差异从基线4.3单位增至6个月8.0单位,之后持续存在。
- HLA-B27阳性、较长病程和较高CRP降低性别差异幅度,周围关节炎和较晚年份启动TNFi增加差异。
核心结论
- 在开始首次TNFi治疗的axSpA患者中,BASDAI和BASFI的基线性别差异在治疗6个月后增加两倍并持续存在,女性评分更差。
- 若干基线特征可调节性别差异,但无一能完全解释这些差异。
研究设计与样本
- 数据来自15个EuroSpA注册中心,纳入开始首次TNFi治疗且每个分析的PROM(BASDAI和BASFI,量表0-100)至少有2次测量的axSpA患者。
- 采用线性混合模型分析24个月内PROM的性别差异,并评估基线特征与观察到的性别差异的关系。
主要发现
- BASDAI分析纳入13 102例(38%女性),BASFI分析纳入10 623例(38%女性)。
- 随访中BASDAI平均性别差异从基线4.3单位(95% CI,3.5-5.1)增至6个月8.0单位(7.2-8.8)。
- BASFI平均性别差异从基线2.2单位(1.4-3.1)增至6个月4.6单位(3.6-5.5),女性评分始终更差。
- 基线特征不能实质性解释随时间观察到的性别差异;HLA-B27阳性、较长病程和较高CRP水平降低性别差异幅度,较晚年份启动TNFi和周围关节炎增加性别差异幅度。
局限性
- 基线特征不能实质性解释随时间观察到的性别差异,且无一能完全解释这些差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate sex differences in patient-reported outcome measures (PROMs) among axSpA patients initiating their first TNFi and identify factors contributing to these disparities over the follow-up. METHODS: Data were included from 15 EuroSpA registries and consisted of axSpA patients initiating their first TNFi, with ≥2 measurements for each analysed PROM (BASDAI and BASFI, scale 0-100) taken at any time point. Linear mixed models were employed to analyse sex differences in PROMs over 24 months and to evaluate how baseline characteristics were related to the observed sex differences. RESULTS: We analysed 13 102 (38% women) in the BASDAI analyses and 10 623 (38% women) in the BASFI analyses. At follow-up, mean sex differences in BASDAI increased from 4.3 units at baseline (95% CI, 3.5-5.1) to 8.0 (7.2-8.8) at 6 months, and in BASFI from 2.2 (1.4-3.1) to 4.6 (3.6-5.5), with consistently worse scores in women. Baseline characteristics could not substantially account for the observed sex differences over time; however, the magnitude of the sex differences was reduced by HLA-B27 positivity, longer disease duration, and increased CRP levels, but increased by TNFi initiation in later years and peripheral arthritis. CONCLUSION: In axSpA patients initiating their first TNFi, baseline sex differences in BASDAI and BASFI increased two-fold after 6 months of treatment and persisted thereafter, with worse scores in women. Several baseline characteristics moderated the sex differences, though none could fully account for them. These findings improve our understanding of sex differences and underscore their importance in axSpA.
引用
- Hellamand P, van de Sande MGH, Nurmohamed MT, et al. Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors. Rheumatology (Oxford). 2025. PMID: 39041780. doi:10.1093/rheumatology/keae370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。